文献速递肾移植

肾移植受者由钙调磷酸酶抑制剂转为贝拉西普维持免疫抑制的随机3b期试验

Conversion from Calcineurin Inhibitor- to Belatacept-Based Maintenance Immunosuppression in Renal Transplant Recipients: A Randomized Phase 3b Trial.
PubMed 文献 · J Am Soc Nephrol · 2021-12-01

本随机3b期试验将446例稳定期肾移植受者按1:1分为转换为贝拉西普组或继续CNI组,主要终点为24个月带功能移植物存活率。结果显示两组生存率相似(98%对97%),贝拉西普组eGFR更高、dnDSA发生率更低,但BPAR发生率数值上更高(8%对4%)。

要点

  • 稳定期肾移植受者由CNI转为贝拉西普,24个月带功能移植物存活率与继续CNI相当。
  • 贝拉西普组24个月eGFR更高(55.5对48.5 ml/min/1.73m²)。
  • 贝拉西普组BPAR发生率数值更高(8%对4%),dnDSA发生率更低(1%对7%)。

核心结论

  • 稳定期肾移植受者由CNI转为贝拉西普维持免疫抑制,死亡或移植物丢失率与继续CNI相似,肾功能改善,BPAR数值上更高但dnDSA更低。

研究设计与样本

  • 随机、开放标签3b期试验,纳入移植后6-60个月、稳定期、接受CNI维持治疗的成人肾移植受者446例,1:1随机分为转换为贝拉西普组(n=223)或继续CNI组(n=223),主要终点为24个月带功能移植物存活率。

主要发现

  • 24个月带功能移植物存活率贝拉西普组98%、CNI组97%(校正差值0.8;95.1%CI -2.1至3.7)。
  • 经活检证实的急性排斥反应(BPAR)发生率贝拉西普组8%、CNI组4%。
  • 新发供者特异性抗体(dnDSA)发生率贝拉西普组1%、CNI组7%。
  • 24个月eGFR贝拉西普组55.5 ml/min/1.73m²、CNI组48.5 ml/min/1.73m²。
  • 两组严重不良事件、感染和停药率相似,贝拉西普组1例发生移植后淋巴增殖性疾病。

临床怎么用

  • 对于稳定期肾移植受者,可考虑由CNI转为贝拉西普以改善肾功能并降低dnDSA风险,但需权衡BPAR风险数值上的增加。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Calcineurin inhibitors (CNIs) are standard of care after kidney transplantation, but they are associated with nephrotoxicity and reduced long-term graft survival. Belatacept, a selective T cell costimulation blocker, is approved for the prophylaxis of kidney transplant rejection. This phase 3 trial evaluated the efficacy and safety of conversion from CNI-based to belatacept-based maintenance immunosuppression in kidney transplant recipients. METHODS: Stable adult kidney transplant recipients 6-60 months post-transplantation under CNI-based immunosuppression were randomized (1:1) to switch to belatacept or continue treatment with their established CNI. The primary end point was the percentage of patients surviving with a functioning graft at 24 months. RESULTS: Overall, 446 renal transplant recipients were randomized to belatacept conversion ( n =223) or CNI continuation ( n =223). The 24-month rates of survival with graft function were 98% and 97% in the belatacept and CNI groups, respectively (adjusted difference, 0.8; 95.1% CI, -2.1 to 3.7). In the belatacept conversion versus CNI continuation groups, 8% versus 4% of patients experienced biopsy-proven acute rejection (BPAR), respectively, and 1% versus 7% developed de novo donor-specific antibodies (dnDSAs), respectively. The 24-month eGFR was higher with belatacept (55.5 versus 48.5 ml/min per 1.73 m 2 with CNI). Both groups had similar rates of serious adverse events, infections, and discontinuations, with no unexpected adverse events. One patient in the belatacept group had post-transplant lymphoproliferative disorder. CONCLUSIONS: Switching stable renal transplant recipients from CNI-based to belatacept-based immunosuppression was associated with a similar rate of death or graft loss, improved renal function, and a numerically higher BPAR rate but a lower incidence of dnDSA.Clinical Trial registry name and registration number: A Study in Maintenance Kidney Transplant Recipients Following Conversion to Nulojix® (Belatacept)-Based, NCT01820572.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Budde K, Prashar R, Haller H, et al. Conversion from Calcineurin Inhibitor- to Belatacept-Based Maintenance Immunosuppression in Renal Transplant Recipients: A Randomized Phase 3b Trial. J Am Soc Nephrol. 2021. PMID: 34706967. doi:10.1681/ASN.2021050628

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。